参考文献:
1.Ben-Ami, E., C. M. Barysauskas, S. Solomon, K. Tahlil, R. Malley, M. Hohos, K. Polson, M. Loucks, M. Severgnini, T. Patel, A. Cunningham, S. J. Rodig, F. S. Hodi, J. A. Morgan, P. Merriam, A. J. Wagner, G. I. Shapiro and S. George (2017). "Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study." Cancer 123(17): 3285-3290.
2.Burgess, M. A., V. Bolejack, S. Schuetze, B. A. V. Tine, S. Attia, R. F. Riedel, J. S. Hu, L. E. Davis, S. H. Okuno, D. A. Priebat, S. Movva, D. R. Reed, S. P. D'Angelo, A. J. Lazar, E. Z.-Y. Keung, D. K. Reinke, L. H. Baker, R. G. Maki, S. Patel and H. A.-H. Tawbi (2019). "Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts." Journal of Clinical Oncology 37(15_suppl): 11015-11015.
3.Hoption Cann, S. A., J. P. van Netten and C. van Netten (2003). "Dr William Coley and tumour regression: a place in history or in the future." Postgraduate Medical Journal 79(938): 672-680.
4.Italiano, A., A. Bessede, M. Pulido, E. Bompas, S. Piperno-Neumann, C. Chevreau, N. Penel, F. Bertucci, M. Toulmonde, C. Bellera, J. P. Guegan, C. Rey, C. Sautès-Fridman, A. Bougoüin, C. Cantarel, M. Kind, M. Spalato, B. Dadone-Montaudie, F. Le Loarer, J. Y. Blay and W. H. Fridman (2022). "Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort." Nature Medicine 28(6): 1199-1206.
5.Maki, R. G., A. A. Jungbluth, S. Gnjatic, G. K. Schwartz, D. R. D'Adamo, M. L. Keohan, M. J. Wagner, K. Scheu, R. Chiu, E. Ritter, J. Kachel, I. Lowy, L. J. Old and G. Ritter (2013). "A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma." Sarcoma 2013: 168145.
6.Sousa, L. M., J. S. Almeida, T. Fortes-Andrade, M. Santos-Rosa, P. Freitas-Tavares, J. M. Casanova and P. Rodrigues-Santos (2021). "Tumor and Peripheral Immune Status in Soft Tissue Sarcoma: Implications for Immunotherapy." Cancers 13(15): 3885.
7.Tawbi, H. A., M. Burgess, V. Bolejack, B. A. Van Tine, S. M. Schuetze, J. Hu, S. D'Angelo, S. Attia, R. F. Riedel, D. A. Priebat, S. Movva, L. E. Davis, S. H. Okuno, D. R. Reed, J. Crowley, L. H. Butterfield, R. Salazar, J. Rodriguez-Canales, A. J. Lazar, Wistuba, II, L. H. Baker, R. G. Maki, D. Reinke and S. Patel (2017). "Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial." Lancet Oncol 18(11): 1493-1501.